Combination Inhalers for Upper Airway Diseases

Chart_Collage_160  Published August 2015  •  Catalog no. DHJ554F •  Price US $3,850

Combination inhalers for upper airway diseases – oral inhalers containing two drugs that complement the therapeutic actions of one another – have seen a significant increase in development activity and product proliferation in the past five years. Growth is being driven by improved patient experience as derived from ease-of use (fewer devices/medications to administer) and for many patients improved control of symptoms associated with upper airway diseases. Combination inhalers most commonly consist of an inhaled corticosteroid in combination with a bronchodilator. These products are realizing significant commercial success in the two markets for which they are indicated – Asthma and COPD – both of which are forecast to grow at impressive rates for the remainder of the decade.

Bar_Graph  Combination Inhalers for Upper Airway Diseases Report Prospectus (Download PDF)

Blue document   Combination Inhalers for Upper Airway Diseases Report Order Form (Download PDF)


What You Will Learn

•    Analyzes the market for combination (dual drug) oral inhalers
•    Assesses oral inhalation device technology for delivering multiple drugs, and evaluates product technology issues and evolving market factors
•    Provides detailed assessments of combination drug inhalers, their growth prospects and market potential
•    Evaluates development-stage dual therapy inhalers and assesses likely market entry timelines
•    Provides market data and forecasts for dual drug oral inhaler products to 2022
•    Profiles inhaled drug product market participants, their technology, product development activity, and business strategies
•    Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners

Summary of Contents

Executive Summary

Orally Inhaled Corticosteroid Market Overview

The Upper Respiratory Therapeutics Marketspace
Therapeutic Targets for Combination Inhalers
Competing Drug Treatments
Demand Drivers
Technology Factors
Competitive Landscape

Asthma Market Risks and Opportunities

Global Patient Demographics
Regional Market Drivers
The Growing Therapeutic Need

Inhaler Technologies for Delivering Combination Therapies

Dry Powder Inhalers
DPI Formulation Technology
Characteristics and Parameters
DPI Excipients and Packaging
Metered Dose Inhalers
MDI Device Selection Criteria
Ease-of-Use Factors

Combination Inhalers – Product Analysis, Market Data & Forecasts

Albuterol/Ipratropium (Nebulizer)
Albuterol/Ipratropium (MDI)
Generic Albuterol/Ipratropium Solution
Fluticasone/Vilanterol (DPI)
Fluticasone/Salmeterol (MDI)
Fluticasone/Salmeterol (DPI)
Budesonide/Formoterol (MDI)
Formoterol/Mometasone  (MDI)
Umeclidinium/Vilanterol (DPI)

Development-stage Combination Inhalers

Dry Powder Formulations
Metered Dose Formulations
Nebulized Solutions

Therapeutic Market Assessment

Demand Factors
Regional Market Factors
Demand Factors
Regional Market Factors

Market Factors

Regulatory Issues
Patient Compliance
Prescribing Trends
Healthcare Economics
Regional Market Factors
Connected Devices

Market Sector Company Profiles